Welcome to the e-CCO Library!

P716: A 2-week course of Exclusive Enteral Nutrition followed by the Crohn Disease Exclusion Diet is effective for Induction and Maintenance of Remission in children with Crohn Disease; the DIETOMICS-CD trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sigall-Boneh, R.(1,2)*;Manuel Navas-López, V.(3); Hussey, S.(4);Pujol Muncunill, G.(5);Lawrence, S.(6);Jonsson Rolandsdotter, H.(7,8);Otley, A.(9);Martín-de-Carpi5, J.(5);Abramas, L.(1);Herrador López , M.(10);Egea Castillo, N.(11);Chen, M.(12);Hurley, M.(13);Wingate, K.(14);Olen, O.(15,16);yaakov, M.(1);Levine, A.(1,17);Van Limbergen, J.(18,19);Wine, E.(12);
Created: Friday, 14 July 2023, 11:12 AM
P716: Beta-blocker use is associated with a higher relapse risk of inflammatory bowel disease – a Dutch retrospective cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Willemze R.*1, Bakker T.1, Pippias M.2, Ponsioen C.3, de Jonge W.1

Created: Wednesday, 20 February 2019, 10:36 AM
P716: Current smoking trends in British IBD patients in the age of e-cigarettes
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Loonat, R. Sagar, C. Selinger*

Created: Thursday, 21 February 2019, 9:14 AM
P716: Exclusive Enteral Nutrition refurbishes beneficial gut microbiota in patients with Acute Severe Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Bajaj, A.(1);Markandey, M.(1);Sahu, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Kumar, P.(1);Singh, N.(1);Gupta, A.(1);Singh, M.(1);Verma, M.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
Created: Friday, 11 February 2022, 3:56 PM
P716: The use of tacrolimus in patients with ulcerative colitis resistant to standard medical therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Shafi*1, A. Bedir2, L. Medcalf1, G. Chung-Faye1, B. Hope1, P. Dubois1, B. Hayee1, B. Vadamalayan1, A. J. Kent1

Created: Friday, 22 February 2019, 9:41 AM
P717 Ustekinumab in Crohn’s disease: Real-world outcomes from the Sicilian Network for inflammatory bowel diseases (SN-IBD):–Preliminary results
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Viola1, G. Fiocco1, A. Alibrandi2, F.S. Macaluso3, M. Cappello4, A.C. Privitera5, G. Magrì6, S. Garufi7, A. Centritto1, M. Ventimiglia3, E. Giuffrida4, C. Ferracane6, G. Costantino1, S. Renna3, A. Orlando3, W. Fries1

Created: Thursday, 30 January 2020, 10:12 AM
P717: Comparison of two different techniques to assess vedolizumab trough levels in adult patients with IBD
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Berger1*, C. Christ1, F.-P. Armbruster1, H. Schulze2, A. Dignass2,3, J. Stein3,4, K. Farrag3,4

Created: Thursday, 21 February 2019, 9:14 AM
P717: Faecal Microbiota Transplant in Ulcerative Colitis (FMTUC) – A randomised clinical trial feasibility study
Year: 2022
Source: ECCO'22
Authors: Jitsumura, M.(1,2);Cunningham , A.(1);Hitchings, M.D.(3);Wilkinson, T.(3);Kinross, J.(4);Row, P.(5);Davies, A.(6);Dean Anthony, H.(1);
Created: Friday, 11 February 2022, 3:56 PM
P717: Higher ulcerative colitis/Crohn's disease ratio in a central region of Argentina
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Balderramo D.*1, Herrera-Najum P.2, Trakal J.3, Gonzalez R.1, Zárate F.4, Raiden K.5, Ferrer L.2, Balzola S.5, Defagό M.R.6 Grupo CEMEI (Cooperaciόn para el Estydio y Manejo de la Enfermedad Inflamatoria Intestinal) Cόrdoba, Argentina

Created: Wednesday, 20 February 2019, 10:36 AM
P717: The use of combination biologic therapy in inflammatory bowel disease: A single tertiary-centre experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Panaccione*1, K. Novak1, C. Seow1, S. Devlin1, C. Lu1, J. Heatherington1, M-L. Martin1, G. Kaplan1, R. Panaccione1

Created: Friday, 22 February 2019, 9:41 AM
P717: Use of tramadol versus traditional opioids and adverse outcomes of Inflammatory Bowel Diseases: a Danish nationwide cohort study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dalal, R.(1)*;Lund, K.(2);Zegers, F.(2);Friedman, S.(1);Allegretti, J.(1);Norgard, B.(2);
Created: Friday, 14 July 2023, 11:12 AM
P718 Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Matar1, R. Shamir1, D. Turner2, E. Broide3, B. Weiss4, O. Ledder2, A. Guz-Mark1, F. Rinawi1, S. Cohen5, C. Topf Olivestone6, R. Shaul7, S. Ben-Horin8, A. Assa1

Created: Thursday, 30 January 2020, 10:12 AM
P718: A Phase I Study of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Pediatric Perianal Fistulizing Crohn's Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Otero Piñeiro, A.(1)*; Lightner , A.L.(1);Reese , J.(2);Ream , J.(3);Nachand , D.(4);Adams , A.(5);VanDenBossche, A.(1);Kurowski, J.(6);
Created: Friday, 14 July 2023, 11:12 AM
P718: Characterization of microbiota and metabolomic profile in human colonic surgical resections of UC patients
Year: 2022
Source: ECCO'22
Authors: Bauset, C.(1);Carda-Diéguez, M.(2);Buetas, E.(2);Lis-López, L.(1);Navarro, F.(3);Ortiz-Masiá, D.(4);Calatayud, S.(1);Barrachina, M.D.(1);Mira, Á.(2);Cosín-Roger, J.(5);
Created: Friday, 11 February 2022, 3:56 PM
P718: Discrepancies between patients’ preferences and physicians’ preference perception for oral formulations: A real-life survey
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Marchi1*, S. Timeus1, L. Mackenzie-Smith1, P. Le Calvé2, R. Young2

Created: Thursday, 21 February 2019, 9:14 AM
P718: Risk of tuberculosis in patients with inflammatory bowel disease receiving biologics using two interferon-γ release assays as monitoring
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. de Francisco*1,2, M. Arias-Guillén3, A. Castaño-García1, I. Pérez-Martínez1, J. J. Palacios4, V. Rolle-Sóñora2, S. Martínez-González1, V. Jiménez-Beltrán1, N. Rodríguez-Ferreiro1, P. Flórez-Díez1, A. Suárez1,2, S. Riestra1,2

Created: Friday, 22 February 2019, 9:41 AM
P718: The epidemiology of IBD differs in South Asian migrants compared to Caucasians; results from a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Misra R.*1, Faiz O.2, Burisch J.3, Munkholm P.3, Arebi N.4

Created: Wednesday, 20 February 2019, 10:36 AM
P719 Effectiveness and safety of ustekinumab induction therapy in ulcerative colitis: A GETAID real-world cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Amiot1, A. Vered2, J. Filippi3, G. Cadiot4, D. Laharie5, S. Melanie6, R. Altwegg7, Y. Bouhnik8, L. Peyrin-biroulet9, C. Gilletta10, X. Roblin11, G. Pineton de chambrun7, L. Vuitton12, A. Bourrier13, S. Nancey14, J.M. Gornet15, S. Nahon16, G. Bouguen17, S. Viennot18, P. Benjamin19, M. Fumery20, GETAID

Created: Thursday, 30 January 2020, 10:12 AM
P719: Determinants of tobacco consumption in the Swiss IBD cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Grueber M.*1, Clair Willi C.2, Allez M.3, Biedermann L.4, Fournier N.5, Schöpfer A.6, Vavricka S.7, Juillerat P.8, Macpherson A.J.9

Created: Wednesday, 20 February 2019, 10:36 AM
P719: Does radiation to the pelvis portend worse ileal pouch outcomes? An international multi-institution collaborative study
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Lightner1*, A. Spinelli2, N. McKenna1, J. Warusavitarne3, P. Fleshner4

Created: Thursday, 21 February 2019, 9:14 AM